Peptides Lab UK Research Quality Standards: Our Full SOP for HPLC Verification, Mass Spectrometry Identity, Endotoxin Testing and Batch Traceability (2026)

Last updated: April 2026 · UK research-grade reference · Quality standards SOP documentation

Table of Contents

• 1. Our quality principles
• 2. Synthesis and production standards
• 3. HPLC purity verification
• 4. Mass spectrometry identity confirmation
• 5. Independent third-party verification
• 6. Endotoxin testing
• 7. Residual solvent analysis
• 8. Water content analysis
• 9. Sequence verification
• 10. Certificate of Analysis — what we provide
• 11. Batch traceability
• 12. Cold-chain shipping and packaging
• 13. Storage and shelf-life
• 14. Returns and analytical recourse
• 15. Openness — how to verify our claims
• 16. Industry standards we reference
• FAQ
• References and standards citations

1. Our quality principles

Peptides Lab UK operates to six non-negotiable quality principles:

1. Independent third-party verification. Every batch of peptide we supply is tested by an analytical laboratory with no ownership relationship to our synthesis or procurement partners. The entity with commercial incentive to report high purity is not the entity responsible for the measurement.
2. Batch-specific documentation. No “representative” COAs. Every Certificate of Analysis is for the specific production batch you receive, with a batch number matching the physical vial label.
3. Quantitative reporting. We report numbers, not adjectives. “Purity ≥98%” without an actual percentage is not acceptable; our COAs quote the measured value to one decimal place.
4. Full documentation chain. From synthesis batch to UK delivery, we maintain chain-of-custody records. Ask us — we will show them.
5. Transparent analytical methodology. The HPLC column, mobile phase, gradient, and detection method are documented with every report. Your lab can reproduce our conditions if you want to verify.
6. Defensible recourse. If your own analytical verification produces a result substantially different from our stated specification, we respond constructively — re-testing, cross-verification, or refund, as the situation requires.

2. Synthesis and production standards

Our peptides are produced by partner laboratories operating to international solid-phase peptide synthesis (SPPS) standards. Key synthesis parameters:

• Chemistry: Fmoc-based solid-phase synthesis with standard coupling reagents (HBTU, HATU, PyBOP or equivalents)
• Resin: Wang, Rink amide, or 2-chlorotrityl resin as appropriate for the target peptide
• Cleavage: standard TFA-based cleavage cocktails with appropriate scavengers (TIS, water, EDT, phenol)
• Purification: preparative reverse-phase HPLC using standard mobile phase (water + 0.1% TFA / acetonitrile + 0.1% TFA gradient)
• Lyophilisation: standard freeze-drying under vacuum, typically −40°C condenser, with pressure cycling for defined residual moisture

Post-purification and lyophilisation, each batch undergoes analytical characterisation before release.

3. HPLC purity verification

Reversed-phase HPLC (RP-HPLC) is the primary purity determination method. Standard conditions:

• Column: C18 reversed-phase (typical 4.6 × 250 mm, 5 µm particle)
• Mobile phase A: water + 0.1% TFA
• Mobile phase B: acetonitrile + 0.1% TFA
• Gradient: peptide-specific, typically 5% B → 95% B over 25-40 min
• Flow rate: 1.0 mL/min
• Detection: UV absorbance at 214 nm (peptide bond) and/or 220 nm
• Injection volume: 10-20 µL at 0.5-1 mg/mL sample concentration

Specification: ≥98% purity by HPLC as measured by the peak-area ratio of the target peak to total integrated area of all detectable peaks. Typical measured values across our catalogue are 99.0-99.7%. We include the full chromatogram with every COA so you can verify peak integration yourself.

4. Mass spectrometry identity confirmation

MS identity confirmation is the complementary analytical to HPLC purity. Standard methods:

• ESI-MS (electrospray ionisation): preferred for most peptides under ~5000 Da; reports protonated molecular ion [M+H]⁺ or multiply-charged species
• MALDI-TOF: used for larger peptides (~5000-10000 Da); reports singly-charged [M+H]⁺ from matrix-assisted desorption
• LC-MS/MS: used for sequence-level verification when complete sequencing confirmation is required

Reporting: our COAs state the theoretical monoisotopic or average mass, the observed mass, and the calculated mass difference. Acceptance criterion: |observed − theoretical| < 1 Da for standard peptides; < 2 Da for larger peptides with acceptable MS resolution.

5. Independent third-party verification

Third-party verification means: the analytical testing laboratory has no ownership, no financial relationship, and no commercial interest in reporting high purity. Our third-party analytical partners are UK- or EU-based laboratories operating under ISO 17025 accreditation or equivalent quality management systems.

For each batch we supply:

• Manufacturer-provided COA (from the synthesis partner)
• Independent third-party confirmation (re-testing at the analytical partner laboratory)
• Cross-check: any disagreement between manufacturer and third-party results is flagged and investigated before release

We will share the name and accreditation status of our analytical partners with customers on request, subject to our partners’ commercial confidentiality preferences.

6. Endotoxin testing

Bacterial endotoxin (lipopolysaccharide, LPS) quantification follows USP <85> or European Pharmacopoeia 2.6.14. Method options:

• LAL (Limulus Amebocyte Lysate): classical pharmacopoeial method; reports EU/mg peptide
• rFC (recombinant Factor C): modern animal-free alternative

Specification: <1 EU/mg for research-grade peptide suitable for most in vitro and preclinical applications. Research applications requiring lower endotoxin (primary macrophage culture, inflammation research) should request our low-endotoxin specification — additional ultrafiltration and endotoxin-depletion steps bring typical levels to <0.1 EU/mg.

7. Residual solvent analysis

Residual organic solvent analysis by gas chromatography (GC) or headspace-GC-MS follows ICH Q3C guidance. Analytes reported:

• Acetonitrile: <410 ppm (ICH Class 2 limit)
• Trifluoroacetic acid (TFA): <1000 ppm (~0.1%) — our typical specification
• Dimethylformamide (DMF): <880 ppm (ICH Class 2 limit)
• Dichloromethane (DCM): <600 ppm (ICH Class 2 limit)
• Methanol: <3000 ppm (ICH Class 2 limit)

All our batches are verified to meet or exceed ICH Q3C Class 2 limits. TFA is the most clinically-relevant residual for peptides because of its G-protein-coupled-receptor activity at supra-physiological concentrations; our typical TFA residual specification <0.1% is comfortably below the regulatory limit.

8. Water content analysis

Water content by Karl Fischer titration or equivalent. Lyophilised peptide typical water content: 3-8%. Higher water content indicates incomplete lyophilisation and accelerated degradation; our specification: <10% residual water.

9. Sequence verification

For research-grade peptide supply, MS identity confirmation is the primary sequence-level check. Full amino acid sequencing (Edman degradation or LC-MS/MS fragmentation) is available on request for applications where complete sequence confirmation is required — e.g. publication-grade research, regulatory-referenced studies, or novel-sequence verification.

10. Certificate of Analysis — what we provide

Every batch ships with a COA that includes:

• Peptide name, sequence, molecular formula, theoretical molecular weight
• Batch number, matching the physical vial label
• Production date and expiry/retest date
• HPLC purity (%), with chromatogram
• Mass spectrometry: theoretical mass, observed mass, method used
• Endotoxin result (EU/mg)
• Residual solvent results (each analyte with ppm value)
• Water content (%)
• Appearance description
• Testing laboratory identification
• Signatory, testing date, and laboratory accreditation reference

The COA is supplied in PDF and, where available, a QR-verified digital certificate linking to the testing laboratory’s record.

11. Batch traceability

For every vial we ship, we can produce on request:

• Synthesis batch number and production date
• Purification batch number (if different from synthesis batch)
• Analytical batch number (if testing was run on a sub-batch)
• Lyophilisation batch number and date
• Fill and finish batch number
• Shipping manifest with cold-chain data logger trace (where applicable)

Chain-of-custody records are retained for a minimum of 7 years from ship date.

12. Cold-chain shipping and packaging

Shipping policy:

• Ambient: suitable for stable lyophilised peptides on short UK domestic deliveries (1-2 days)
• Ice pack insulated: standard for most temperature-sensitive peptides on 2-4 day deliveries
• Dry ice: available for extended-duration or international shipments of highly temperature-sensitive material
• Temperature data loggers: available for research protocols requiring documented cold-chain integrity

All shipments include UK-based customs documentation (not applicable for UK domestic deliveries), research-use-only labelling, and a packing slip with COA reference.

13. Storage and shelf-life

Lyophilised peptide shelf-life at −20°C is typically 2-3 years from production date. Our stated expiry/retest date on each vial is the later of: (a) 2 years from production or (b) the stability-tested expiry of the specific sequence.

Post-reconstitution storage is peptide-specific:

• GLP-1 agonists (semaglutide, tirzepatide, retatrutide): 2-8°C, 30-56 days
• Regenerative peptides (BPC-157, TB-500): 2-8°C, 30-45 days
• Growth-hormone secretagogues: 2-8°C, 30-45 days
• Melanocortin peptides: 2-8°C, 30-45 days
• Copper peptides (GHK-Cu): 2-8°C, 30-45 days, protect from light

Detailed reconstitution and storage guidance for each peptide is available in our reconstitution calculator and the respective research reference pages.

14. Returns and analytical recourse

If your own analytical verification produces a result substantially different from our stated specification, we take the challenge seriously. Protocol:

1. Contact us with the result and the method details
2. We will provide the original analytical record and the independent third-party report for cross-comparison
3. If results differ beyond normal analytical variance (typically ~0.5 percentage point HPLC purity), we will re-test the retained control sample at an independent analytical laboratory
4. If the retest confirms your measurement, we replace the batch at no charge or refund
5. If the retest confirms our original specification, we share both results with you for independent arbitration

This is “trust but verify” in commercial form. We stand behind our specifications because they are supported by the underlying analytical record.

15. Openness — how to verify our claims

Every claim on this page can be independently verified. Some options:

• Request a sample COA: we can provide a redacted sample COA showing the format, data fields, and analytical output
• Request analytical partner identification: subject to commercial confidentiality, we share the names and ISO 17025 accreditation numbers of our third-party testing partners
• Run your own analytical verification: any peptide we ship can be re-tested at any UK-based analytical laboratory; the HPLC method parameters are published above for reproducibility
• Ask for a technical conversation: for UK research customers, we offer a technical call with our analytical oversight team to walk through any specific quality question

Our approach is: make the claim, document the claim, and stand behind the claim. The alternative — opaque quality practices — is not compatible with reproducibility research.

16. Industry standards we reference

Our quality framework references and aligns with:

• ISO/IEC 17025:2017 — general requirements for the competence of testing and calibration laboratories
• ICH Q3C — residual solvents guidance
• ICH Q6A — specifications for new drug substances
• USP <85> — bacterial endotoxin test
• USP <1086> — impurities in drug substances and drug products
• European Pharmacopoeia 2.6.14 — bacterial endotoxins
• European Pharmacopoeia 5.1.4 — microbiological quality

While research-grade peptide supply is not directly regulated by the MHRA in the way pharmaceutical-grade products are, we align our quality framework with pharmaceutical-grade standards where applicable. This ensures that peptides supplied for early-phase research are suitable for progression to later-stage work without quality-related re-sourcing.

FAQ

Are you MHRA-regulated?
No — research-grade peptides for in vitro laboratory use are outside MHRA’s pharmaceutical-product regulation. Our quality framework voluntarily aligns with pharmaceutical-grade standards (ICH, USP, EP) to ensure research applications are fully supported.

What is your typical HPLC purity across the catalogue?
99.0-99.7% across our current catalogue. Specific peptide values are reported on the batch-specific COA.

How quickly can you provide a COA after purchase?
The COA accompanies every shipment. If you require the COA before purchase for procurement approval, we can send the specific-batch COA on request — typical response 1-2 business days.

Do you test every batch or spot-check?
Every batch. No batch is released without the full analytical panel completed.

What’s the difference between “research-grade” and “pharmaceutical-grade”?
Pharmaceutical-grade (cGMP) peptide is produced under full pharmaceutical quality management with documented deviations handling, change control, and regulatory filing. Research-grade peptide meets defined analytical specifications but without the full cGMP overlay. For laboratory research use, research-grade is appropriate. For human clinical trial use, cGMP is required.

Are your peptides suitable for in vivo rodent research?
Yes, with appropriate endotoxin specification. Our standard <1 EU/mg endotoxin spec is suitable for most rodent research; our low-endotoxin specification (<0.1 EU/mg) is available for sensitive preclinical models.

Can I request additional testing beyond the standard COA?
Yes. Additional testing — full sequencing (LC-MS/MS), extended impurity profiling, specific heavy-metal analysis — is available on request with typical turnaround of 2-3 weeks at an additional analytical cost.

References and standards citations

1. International Conference on Harmonisation (ICH) Q3C: Impurities: Guideline for Residual Solvents. 2018 revision.
2. International Conference on Harmonisation (ICH) Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products.
3. ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories.
4. United States Pharmacopeia (USP) <85> Bacterial Endotoxins Test.
5. United States Pharmacopeia (USP) <797> Pharmaceutical Compounding — Sterile Preparations.
6. United States Pharmacopeia (USP) <1086> Impurities in Drug Substances and Drug Products.
7. European Pharmacopoeia 2.6.14 Bacterial Endotoxins.
8. European Pharmacopoeia 5.1.4 Microbiological Quality of Pharmaceutical Preparations.
9. Vergote V et al. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci 2009;15:697–710.
10. D’Hondt M et al. Related impurities in peptide medicines. J Pharm Biomed Anal 2014;101:2–30.

UK Research Cluster Hubs

• GLP-1 Research Hub
• Tirzepatide Hub
• Retatrutide Hub
• BPC-157 Research Hub
• TB-500 Research Hub
• Growth-Hormone Peptides Hub
• Research-Grade Buyer’s Guide

Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.